Denosumab for glucocorticoid-induced osteoporosis

Abstract

Osteoporotic fractures are one of the principal adverse effects resulting from the therapeutic use of glucocorticoids. These fractures contribute substantially to morbidity in patients who already have major disabling chronic diseases. The prevention of these fractures is, therefore, a high priority in patients who require glucocorticoids, particularly older patients.